Press Releases

EastGate Biotech Corp. enters into a 3-way International Distribution Agreement with Dr. Upadhyay Vedic Research Laboratories and ImmunoJuvenate, Inc.

May 17, 2021 by admin

The terms of the distribution agreement allow ImmunoJuvenate to market an entire product catalog under Private label in the United States, Canada, and international markets

Read more

EastGate Biotech Pakistan Expands its Collaboration in Advancing the Development of a New Vaccine Against COVID-19

February 18, 2020 by admin

Joint Venture Collaboration to also pursue antibiotic products to create a pipeline to fight various new strains of flu illnesses

Read more

EastGate Biotech Discusses Their Phase 3 Clinical Trials and Recent Coronavirus Agreement

February 5, 2020 by admin

EastGate Biotech Discusses Their Phase 3 Clinical Trials and Recent Coronavirus Agreement

Read more

EastGate Biotech Pakistan Receives International Marketing Rights of Anaferon an Approved Coronavirus Treatment to Potentially Combat the Wuhan Coronavirus

January 30, 2020 by admin

EastGate Biotech Corp. announced today that the company along with its partner EastGate Biotech Pakistan has signed a Memorandum of Understanding (MOU) for the international marketing rights of Anaferon for the treatment of the novel 2019 Coronavirus, commonly called the Wuhan Coronavirus

Read more

EastGate Biotech Provides Summary of 2019 Corporate and Development Highlights

December 30, 2019 by admin

Eastgate Biotech Corp. provides a end of year 2019 Corporate and Development Highlights.

Read more

EastGate Biotech Expands Pipeline to Alzheimer’s Disease Using its Alternative Insulin Delivery Platform

November 14, 2019 by admin

EastGate Biotech Corp. announced today that it has initiated plans to expand its alternative insulin delivery portfolio to apply to the treatment of Alzheimer’s disease.

Read more

EastGate Biotech Announces Expansion and Restructuring of Joint Venture with its Partner in Pakistan

October 9, 2019 by admin

Key products to be tested, registered and marketed include Insugin for diabetes application, alternative insulin for Alzheimer’s application, and Blood Plasma Derived Products, Human Serum Albumin 20%

Read more

EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day clinical trial on Insugin, its liquid insulin mouth rinse solution.

September 25, 2019 by admin

The Marketing Application Approval in Pakistan will follow subject to completion of the Phase III clinical study that will include up to 200 Type 2 patients.

Read more

Eastgate Biotech Corp (OTC: ETBI) Management Interview

September 11, 2019 by admin

Eastgate’s new COO took time to discuss his role with the company, ETBI’s licensing strategy, and upcoming goals for the next few months which includes the commencement of the Phase III trial for their flagship product, Insugin.

Read more

EastGate Biotech Announces Appointment of Bill Abajian to Lead Licensing and Marketing Phase as Chief Operating Officer

September 5, 2019 by admin

WEST CALDWELL, NJ and TORONTO, ON /NEWMEDIAWIRE/ September 4, 2019/ EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today the appointment of distinguished executive Bill Abajian to lead the licensing and marketing phase of the company as Chief Operating Officer of the company, effective August 27, 2019.

Read more
RSS Icon